Home/Pipeline/K8 Implant

K8 Implant

Geographic Atrophy (GA)

Phase I/IIActive

Key Facts

Indication

Geographic Atrophy (GA)

Phase

Phase I/II

Status

Active

Company

Inflammasome Therapeutics

About Inflammasome Therapeutics

Inflammasome Therapeutics is a private, clinical-stage biotech pioneering a new approach to treating degenerative diseases by targeting chronic inflammasome activation. Its platform is built upon the discovery that certain FDA-approved nucleoside reverse transcriptase inhibitors (NRTIs) inhibit inflammasomes, supported by epidemiological data showing reduced disease incidence in patients taking these drugs. The company has developed safer derivatives called Kamuvudines (K8, K9) and is advancing them in clinical trials for ocular indications including Geographic Atrophy, Diabetic Macular Edema, and Thyroid Eye Disease.

View full company profile

Therapeutic Areas

Ophthalmology Neurodegenerative Diseases Metabolic Diseases

Other Geographic Atrophy (GA) Drugs

Drug	Company	Phase	Status
NGM621	NGM Biopharmaceuticals	Phase 2	Active (Merck-led)
ANX007	Annexon Biosciences	Phase 2	Active - Phase 3-ready
IONIS-FB-LRx	Ionis Pharmaceuticals	Phase 3	Active